STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that members of its Executive Leadership Team will present at the following investor conferences:
Stifel Healthcare ConferenceTuesday, November 15, 2022, at 10:55 a.m. ET
Jefferies London Healthcare ConferenceWednesday, November 16, 2022, at 10 a.m. ET (3 p.m. GMT)
Evercore ISI Healthcare Conference (virtual)Tuesday, November 29, 2022, at 8:25 a.m. ET
Piper Sandler Healthcare ConferenceThursday, December 1, 2022, at 8 a.m. ET
Webcasts of the presentations can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. Archived webcast recordings will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.
MEDIA CONTACT:Annie Spinetta6 Degrees973-768-2170[email protected]
INVESTOR CONTACT:Iris Francesconi, Ph.D.Cara Therapeutics203-406-3700[email protected]
